Update - Zayed National Museum and Bahrain Launch Six-Week Archaeologica… Transport - Dubai RTA Introduces Five-Star Rating System for Taxi Companies… Weather - Rain Expected in Some Areas on November 16 as Temperatures Drop…

Send an Inquiry

Fill in the details below and our team will get back to you.

Healthcare 1 min read 71 views

Worlds First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE.

The first WHO enlisted global clinical Phase III trial of Sinopharm CNBGs inactivated vaccine to battle COVID-19 has started in Abu Dhabi, encouraged by the UAE Leaderships commitment to overcoming the pandemic through a global collaborative effort.

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to initiate the trial of Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG, the worlds sixth-largest vaccine manufacturer.

The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for strong research across multiple ethnicities and expanding its feasibility for global application.

They are being operated by Abu Dhabi Health Services (SEHA) who are providing clinical facilities.

UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate and G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.

Chairperson of the UAE National COVID-19 Clinical Management Committee Dr Nawal Ahmed Alkaabi said: Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic.

We are proud to facilitate the testing process that if successful, leads to the manufacture of a vaccine.

It follows a successful phase I and II trials by Sinopharm in China, resulting in 100% of volunteers generating antibodies.

G42 Healthcare CEO Ashish Koshy said: We are greatly proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial.

Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials.

Jingjin Zhu, President, Biological products, Sinopharm CNBG added: The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background.

We will work intimately with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide.

Related News

More on Healthcare

View all

Comments (0)

Join the conversation

No comments yet. Be the first to share your thoughts!

More News

See all
Business

Big 5 Global 2026: Six French companies to showcase advanced construction technologies in Dubai

Six French companies will present their construction technologies and expertise at Big 5 Global 2026, scheduled to take place from November 23 to 26 at the Dubai World Trade Centre. Supported by Business France, AITENDERS, ALPHI ME, ARIADIS, COMUS, CSTB and QUADRA will showcase solutions across...

Nov 16, 2026 · 3 min
Education

JICE connects UAE students with higher education opportunities in Japan at NAJAH Abu Dhabi 2026

The Japan International Cooperation Center (JICE) welcomed approximately 1,200 visitors to the Japan Pavilion at NAJAH Abu Dhabi 2026, held from October 18 to 21 at ADNEC Centre Abu Dhabi. The initiative introduced students and families to higher education opportunities in Japan through...

Nov 16, 2026 · 2 min
Real Estate

Emirates REIT reports 12% rise in property income as Funds from Operations nearly double in Q3 2026

Emirates REIT (CEIC) PLC reported strong financial results for the nine months ended September 30, 2026, with year-on-year growth in property income, operating profit and Funds from Operations (FFO), alongside improvements in its balance sheet. Equitativa (Dubai) Limited, the manager of Emirates...

Nov 16, 2026 · 2 min
Education

Almasar Alshamil Education outlines vision for future of learning at Education Investment MENA 2026

Almasar Alshamil Education Chief Executive Officer Majed Al Mutairi joined regional education leaders at Education Investment MENA 2026 in Dubai, where discussions focused on the future of learning, the role of technology and the importance of collaboration across the education sector. Held on...

Nov 16, 2026 · 2 min
Trusted by

Our Associates

Brands and organisations that work with Day of Dubai.